FDA Approves Subcutaneous Isatuximab-irfc - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Subcutaneous Isatuximab-irfc

The approval expands subcutaneous use across newly diagnosed and previously treated multiple myeloma.

  • By

  • Kathryn Wighton

  • July 10, 2026

  • 2 min

Share

Clinical Scorecard: FDA Approves Subcutaneous Isatuximab-irfc

At a Glance

CategoryDetail
ConditionMultiple Myeloma
Key MechanismsSubcutaneous administration of isatuximab-irfc in combination with other agents.
Target PopulationAdult patients with multiple myeloma
Care SettingOncology

Key Highlights

  • Approved for use in combination with pomalidomide and dexamethasone for patients with prior therapy.
  • Indicated for relapsed or refractory multiple myeloma with carfilzomib and dexamethasone.
  • Approved for newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of multiple myeloma based on clinical and laboratory criteria.

Management

  • Use in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.

Monitoring & Follow-up

  • Monitor for hypersensitivity reactions, neutropenia, infections, and secondary malignancies.

Risks

  • Warnings include hypersensitivity, neutropenia, infections, secondary malignancies, and embryo-fetal toxicity.

Patient & Prescribing Data

Adult patients with multiple myeloma

Recommended dose is 1,400 mg administered subcutaneously.

Clinical Best Practices

  • Utilize the CirCLIQ on-body delivery system or manual administration with a syringe and infusion set.

Related Resources & Content

Original Source(s)

FDA Approves Subcutaneous Isatuximab-irfc

  • by Kathryn Wighton

  • July 10, 2026

Related Content

Sugar-Sweetened Beverages May Raise Risk of  Hepatic Cancer Subtypes

In a pooled analysis of more than 1.5 million patients, sugar-sweetened beverages were associated with higher risks of HCC and ICC, while artificially-sweetened beverages showed no independent association with hepatic cancer.

Prehabilitation Program May Benefit Patients Undergoing CRC Surgery

Structured implementation increased participation and improved preoperative fitness, while postoperative complication and mortality rates remained similar across groups.

More Physicians Enter Politics

Viewpoint explores how more physician-candidates could reshape both public service and public trust in medicine.